EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Partic
A phase 1/2 trial of Pembrolizumab in colorectal cancer and endometrial cancer, run by Eikon Therapeutics, now recruiting.
Overview
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors is a phase 1/2 interventional study registered as NCT07262619 by Eikon Therapeutics, with 160 participants planned, started 2026-01-20 and due to reach its primary completion in 2029-03. Interventions recorded: EIK1005, pembrolizumab (KEYTRUDA® ). Conditions listed: Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Shares Endometrial cancer, Pembrolizumab, Colorectal cancer.
- TrialA Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
Shares Eikon Therapeutics, Pembrolizumab.
- TrialA Study of DM002 in Patients With Advanced Solid Tumors
Shares Endometrial cancer, Colorectal cancer.
- TrialA Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Shares Endometrial cancer, Colorectal cancer.
- TrialA Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Shares Endometrial cancer, Pembrolizumab.
- TrialA Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Shares Endometrial cancer, Colorectal cancer.
- TrialStudy of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Shares Endometrial cancer, Pembrolizumab.
- TrialStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
Shares Endometrial cancer, Pembrolizumab.